Diabetic retinopathy affects nearly all young patients with type 1 diabetes

Article

One in three young Danish patients with type 1 diabetes mellitus progressed to proliferative diabetic retinopathy, and two in three had 2-step progression despite their young age, according to study results recently published in the November 2013 issue of Acta Diabetologica. In addition, these researchers from Denmark found that after 30-years? duration of diabetes, the presence of diabetic retinopathy was almost universal.

One in three young Danish patients with type 1 diabetes mellitus progressed to proliferative diabetic retinopathy, and two in three had 2-step progression despite their young age, according to study results recently published in Acta Diabetologica. In addition, these researchers from Denmark found that after 30-years' duration of diabetes, the presence of diabetic retinopathy was almost universal.

From 1987 to 1989, these researchers identified a paediatric cohort of children that included approximately 75% of all children in Denmark with type 1 diabetes

In 1995, mean patient age was 21.0 years, and mean duration of diabetes was 13.5 years. The 16-year incidence of proliferative retinopathy was 31.0%, 2-step progression was 64.4% and 2-step regression of diabetic retinopathy was 0.0%. The incidence of diabetic retinopathy was 95.1%.

Upon multivariate logistic regression modelling, progression to proliferative diabetic retinopathy was significantly associated with HbA1c levels in 1995 (OR: 2.61 per 1% increase, 95% CI: 1.85-3.68) and diastolic BP of 1995 (OR: 1.79 per 10 mmHg increase, 95% CI: 1.04-3.07). Two-step progression of diabetic retinopathy was associated with male gender (OR: 2.37 versus female, 95% CI: 1.07-5.27), 1995 HbA1c (OR: 3.02per 1% increase, 95% CI: 2.04-4.48), and 1995 vibration perception threshold (OR: 1.19 per 1 volt increase, 95% CI: 1.02-1.40).

To access these data, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.